Salspera

Executive Summary

Salspera is a private, San Diego-based drug delivery company advancing Saltikva, a novel therapy for Stage 4 metastatic pancreatic cancer. In Phase 2 trial results, Saltikva combined with modified FOLFIRINOX significantly reduced tumor markers and tumor burden while improving progression-free survival and overall survival. Notably, no serious adverse reactions were attributed to Saltikva, suggesting a favorable safety profile. These results position Saltikva as a promising candidate in a difficult-to-treat indication with high unmet need.

Upcoming Catalysts (preview)

• Q1 2027Initiation of Phase 3 Trial for Saltikva60% success
• Q3 2026FDA End-of-Phase 2 Meeting Agreement75% success
• H2 2026Strategic Partnership or Licensing Deal40% success